



Perseus Proteomics Inc.  
Securities Code: 4882 Growth TSE  
August 24, 2022

To all stakeholders,

**PPMX-T003: Announcement on First/Second Patients Dosed in Phase I Clinical Trial  
among Polycythemia Vera (PV) Patients**

Perseus Proteomics Inc. (The Company) is pleased to announce the first and second patients have been dosed PPMX-T003 in the Phase I clinical trial among PV patients.

This trial will primarily investigate the safety and pharmacokinetics in administering PPMX-T003 to patients with PV, a disease where red blood cells (RBCs) multiply at an abnormal level. The secondary purpose is to confirm the therapeutic effects.

In the recruitment of PV patients, the Company has amended the inclusion criteria to be closer to the real-world clinical practice after consultation with the investigators at the medical institutions. The outline of this trial is shown at the [ClinicalTrials.gov](https://clinicaltrials.gov).

The Company expects the phase I clinical trial finishes within this fiscal year, as it has been preparing for the addition of medical institutions.

There is no impact on the financial results forecast for this fiscal year.

■ About PPMX-T003:

PPMX-T003 is an antibody targeting transferrin receptor (TfR) that is related to iron intake into cells. TfR is highly expressed in cells that require much more iron than usual cells: erythroblasts, which are nucleated cells in bone marrow from which RBCs derive, are one of them. When PPMX-T003 binds to TfR, it inhibits cell proliferation by inhibiting iron uptake into erythroblasts. Therefore, it is expected to normalize the number of RBCs of PV patients, who have too many RBCs.

TfR is also expressed in cancer cells that proliferate at a significant pace. PPMX-T003 similarly inhibits proliferation of cancer cells due to its function of inhibition of iron intake. As PPMX-T003 is expected to have therapeutic effects for a wide variety of cancers including acute myeloma leukemia (AML) and aggressive NK-cell leukemia (ANKL), its development has been the main focus of the Company.

[Contact]

Perseus Proteomics Inc.

Administrative Dept. email: [ir@ppmx.com](mailto:ir@ppmx.com)

END